Paradigm Health logo

About Us

About Paradigm Health

Our mission is to create equitable access to clinical trials for any patient, anywhere

Paradigm Health is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for healthcare providers. Incubated by ARCH Venture Partners and backed by leading healthcare and life sciences investors, Paradigm Health aims to break down barriers across the trial ecosystem through one seamless infrastructure implemented at healthcare provider organizations, bringing potentially life-saving therapies to patients faster.

Investors

Stay up to date with the latest Paradigm news, updates and information.

Company History

In 2021, ARCH Venture Partners incubates the company to address the inequities of patient access to clinical research

Paradigm Health emerges from stealth

>$200M Series A funding announced co-led by ARCH Venture Partners and General Catalyst along with F-Prime, GV, Lux Capital, Mubadala, American Cancer Society’s BrightEdge Fund, and others

Strategic partnership announced with Bristol-Myers Squibb

Partnership with Sheba Medical Center and ARC Innovation to transform clinical trials in Israel

Partnership with Fujitsu to launch the Japan-Wide Clinical Trial Network

Leadership

Kent Thoelke
Chief Executive Officer

Kent Thoelke

Chief Executive Officer

Kent Thoelke is a pioneering healthcare executive with over 30 years of clinical research experience. As CEO of Paradigm Health, he leads the company's mission to create equitable access to superior healthcare for patients worldwide. Prior to joining Paradigm Health, Kent served as Chief Innovation Officer at ICON plc following its acquisition of PRA Health Sciences, where he was Chief Scientific Officer. Throughout his career at these organizations, he has driven digital transformation in clinical trials and championed data-driven approaches to make drug development more efficient and equitable across multiple therapeutic areas and geographic regions.

Jonathan Hirsch
Chief Strategy & Growth Officer

Jonathan Hirsch

Chief Strategy & Growth Officer

Jonathan Hirsch is a strategic healthcare leader and serial entrepreneur with extensive experience in clinical research innovation. As Chief Strategy and Growth Officer at Paradigm Health, he drives initiatives to democratize clinical trials and create equitable access to advanced healthcare options for patients worldwide. Prior to joining Paradigm Health, Jonathan served as Co-Founder and Chair of the Advisory Board at Synapticure Inc., while maintaining active investment and advisory roles in pioneering healthcare companies including Arbital Health, Frame, and Thyme Care. Jonathan holds an M.Sci. in Biological Sciences with a specialization in Neuroscience from Stanford University and an A.B. in Biology and Political Science from the University of Chicago.

Jay Trepanier
Chief Financial Officer

Jay Trepanier

Chief Financial Officer

Jay Trepanier is a strategic financial executive with over 30 years of experience in corporate financial operations and business leadership. As Chief Financial Officer at Paradigm Health, he oversees the company's financial strategy and operations, leveraging his extensive experience in private equity and venture capital environments. Prior to Paradigm Health, Jay served as Senior Vice President of FP&A, Global Proposals, and Vendor Management at PRA Health Sciences, Chief Finance and Operations Officer at Science 37, and CEO of Clinverse Inc. Throughout his career, he has successfully led capital raises exceeding $200M and orchestrated eight M&A transactions ranging from $2M to $12B in total value. Jay holds a BS in Business from the University of New Hampshire Peter T. Paul College of Business and Economics, a BS in Accounting from West Virginia University, and is a Certified Public Accountant.

Elijah Meerson
Chief Technology Officer

Elijah Meerson

Chief Technology Officer

Elijah Meerson is an accomplished technology leader with extensive experience building innovative software solutions in healthcare and real estate. As Chief Technology Officer at Paradigm Health, he leads the development of next-generation platforms to optimize clinical research accessibility and efficiency. Prior to Paradigm Health, Elijah served as CTO at Orchard and VP of Engineering at Flatiron Health, where he demonstrated his expertise in scaling engineering teams and delivering transformative technology solutions. He continues to contribute to the technology ecosystem as an advisor to companies including Muru Inc. Elijah holds a B.S. in Computer Science from Georgetown University.

Michelle Lee
Chief Operating Officer

Michelle Lee

Chief Operating Officer

Michelle Lee is a strategic and versatile leader with over 25 years of experience driving operational efficiencies and transformative business strategies across healthcare and technology sectors. As Chief Operating Officer at Paradigm Health, she is responsible for the day to day operations of the business and oversees a broad portfolio of sponsor, provider, and internal facing functions. Prior to joining Paradigm Health, Michelle served as Chief Operating Officer at Vori Health, and has held leadership positions at Honor, Lyric, and McKesson Technology. Michelle holds a B.A from Harvard University and an MBA in Healthcare Management from Wharton.

Board of Directors

Robert Nelsen
Co-founder and Managing Director, ARCH Venture Partners
Hemant Taneja
CEO and Managing Director, General Catalyst
Stephen Knight, MD
President and Managing Partner, F-Prime
Kenneth C. Frazier
Former Executive Chairman & CEO, Merck
General (Ret) Gustave F. Perna
Former COO, Operation Warp Speed
Stephen Klasko, MD MBA
Former CEO, Jefferson Health
Luciana Borio, MD
Former Chief Scientist, U.S. Food & Drug Administration
Elena Viboch
Partner, General Catalyst
Kent Thoelke
Chief Executive Officer

News

Fireside Chat

CEO Kent Thoelke and Mubadala Executive Director Alaa Halawa

Fireside Chat

CEO Kent Thoelke and Mubadala Executive Director Alaa Halawa

Article in New York Times

Start-Up Raises $200 Million to Speed Up Drug Trials

Article in New York Times

Start-Up Raises $200 Million to Speed Up Drug Trials

Press Release

Paradigm Launches with $203 Million to Rebuild the Clinical Research Ecosystem

Press Release

Paradigm Launches with $203 Million to Rebuild the Clinical Research Ecosystem

Press Release

Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials

Press Release

Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials

Press Release

Paradigm and Altru Health System Expand Patient Access to Clinical Trials for Rural Population

Press Release

Paradigm and Altru Health System Expand Patient Access to Clinical Trials for Rural Population

Press Release

Highlands and Paradigm Improve Access to Cancer Care Options in Northwest Arkansas, Increasing Clinical Trial Participation by 45%

Press Release

Highlands and Paradigm Improve Access to Cancer Care Options in Northwest Arkansas, Increasing Clinical Trial Participation by 45%

Press Release

Fujitsu Tackles “Drug Loss” in Japan Through Ecosystem to Accelerate Digitalization of Clinical Trials

Press Release

Fujitsu Tackles “Drug Loss” in Japan Through Ecosystem to Accelerate Digitalization of Clinical Trials

Press Release

Paradigm Partners with Fujitsu to Solve Clinical Trials in Japan

Press Release

Paradigm Partners with Fujitsu to Solve Clinical Trials in Japan

Press Release

Florida Cancer Specialists & Research Institute Launches Partnership with Paradigm Health, Inc. to Expand Patient Access to Lifesaving Clinical Trials

Press Release

Florida Cancer Specialists & Research Institute Launches Partnership with Paradigm Health, Inc. to Expand Patient Access to Lifesaving Clinical Trials

Press Release

Sheba Medical Center, ARC Innovation, and Paradigm Health Inc. Forge Strategic Partnership to Expand and Optimize Global Clinical Trials

Press Release

Sheba Medical Center, ARC Innovation, and Paradigm Health Inc. Forge Strategic Partnership to Expand and Optimize Global Clinical Trials

Press Release

CEO Roundtable on Cancer & Paradigm Health Partner to Launch PACT Collective to Expand Clinical Trial Access & Diversity

Press Release

CEO Roundtable on Cancer & Paradigm Health Partner to Launch PACT Collective to Expand Clinical Trial Access & Diversity

Press Release

New York Cancer & Blood Specialists Launches Partnership with Paradigm Health, Inc. to Expand Patient Access to Clinical Trials

Press Release

New York Cancer & Blood Specialists Launches Partnership with Paradigm Health, Inc. to Expand Patient Access to Clinical Trials

Press Release

NCC will Initiate New Research to Develop a Nationwide Clinical Trial Network, LC-SCRUM-CD (Clinical Development), Supported by PREMIA and Paradigm, to Further Accelerate Precision Medicine for Cancer Patients

Press Release

NCC will Initiate New Research to Develop a Nationwide Clinical Trial Network, LC-SCRUM-CD (Clinical Development), Supported by PREMIA and Paradigm, to Further Accelerate Precision Medicine for Cancer Patients

Is a Paradigm Health Partnership Right for You?